Filana Therapeutics Inc（FLNA）财务数据FLNAFilana Therapeutics Inc

Evaluating the bottom line, Filana Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -55.78%, provide a clear picture of how effectively FLNA converts its operational activities into shareholder value.

In the context of the broader market, FLNA competes directly with industry leaders such as TVGN and BCTX. With a market capitalization of $44.12M, it holds a leading position in the sector. When comparing efficiency, FLNA's gross margin of N/A stands against TVGN's N/A and BCTX's N/A. Such benchmarking helps identify whether Filana Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Filana Therapeutics has shown a consistent pattern of losses, with a net income of -$8.6 million in Q2 2026 and an EPS of -0.18. However, the company's cash position is still relatively strong, with $86.6 million as of March 31, 2026, despite a projected decrease to between $47 million and $50 million by June 30, 2026.